daclatasvir gilead
BMS resubmits hepatitis C drug
March 13, 2015Sales and Marketing BMS, NDA, daclatasvir gilead, hepatitis C, sovaldi
Bristol-Myers Squibb has resubmitted its hepatitis C (HCV) treatment for FDA approval despite previously backing out, as it spots a …
